Integrins in cancer: biological implications and therapeutic opportunities

The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumours. The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. Integrin antagonists, including the αvβ3 and αvβ5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.

[1]  Robert A. Beckman,et al.  Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[2]  J. Munger.  The integrin αvβ6 binds and activates latent TGFβ1 : A mechanism for regulating pulmonary inflammation and fibrosis , 1999 .

[3]  O. G. Ramprasad,et al.  Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic alpha5beta1 integrin receptor and mouse tumor vasculature. , 2008, Journal of medicinal chemistry.

[4]  K. Yoshimatsu,et al.  α6β1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells , 2003, Oncogene.

[5]  F. Aoudjit,et al.  Matrix Attachment Regulates FAS-Induced Apoptosis in Endothelial Cells , 2001, The Journal of cell biology.

[6]  C. Tacchetti,et al.  Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and Leads to Phosphorylation of Specific EGF Receptor Tyrosines* , 2002, The Journal of Biological Chemistry.

[7]  M. Zöller.  Tetraspanins: push and pull in suppressing and promoting metastasis , 2009, Nature Reviews Cancer.

[8]  D. Cheresh,et al.  Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.

[9]  F. Giancotti,et al.  Integrin β4 signaling promotes tumor angiogenesis , 2004 .

[10]  M. Kitajima,et al.  The Relationship Between Bone Metastasis from Human Breast Cancer and Integrin αvβ3 Expression , 2005 .

[11]  T. Byzova,et al.  Prostate cancer specific integrin αvβ3 modulates bone metastatic growth and tissue remodeling , 2007, Oncogene.

[12]  Jonathan R. Lindner,et al.  Noninvasive Assessment of Angiogenesis by Ultrasound and Microbubbles Targeted to &agr;v-Integrins , 2003, Circulation.

[13]  B. Escudier,et al.  A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[14]  S. Santoro,et al.  Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Burgess,et al.  Laminin-10 Mediates Basal and EGF-Stimulated Motility of Human Colon Carcinoma Cells via α3β1 and α6β4 Integrins , 2001 .

[16]  Dai Fukumura,et al.  Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. , 2007, Microvascular research.

[17]  Marie-Liesse Asselin-Labat,et al.  Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.

[18]  J. Tímár,et al.  Multiple Roles for Platelet GPIIb/IIIa and αvβ3 Integrins in Tumor Growth, Angiogenesis, and Metastasis , 2002 .

[19]  X. Bu,et al.  EFFECT OF THE ANGIOGENESIS INHIBITOR CILENGITIDE (EMD 121974) ON GLIOBLASTOMA GROWTH IN NUDE MICE , 2006, Neurosurgery.

[20]  Sejeong Shin,et al.  A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. , 2006, Cancer research.

[21]  Chih-Hsin Tang,et al.  Osteoblasts‐derived TGF‐β1 enhance motility and integrin upregulation through Akt, ERK, and NF‐κB‐dependent pathway in human breast cancer cells , 2008 .

[22]  W. Oyen,et al.  Tumor Targeting with Radiolabeled v 3 Integrin Binding Peptides in a Nude Mouse Model , 2002 .

[23]  J. Lindquist,et al.  Cooperation between VEGF and beta3 integrin during cardiac vascular development. , 2007, Blood.

[24]  David C. Smith,et al.  Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. , 2006, Clinical genitourinary cancer.

[25]  A. Fangberget,et al.  Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  William P Schiemann,et al.  β3 Integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells , 2006, Breast Cancer Research.

[27]  Fan Wang,et al.  Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[28]  David A. Cheresh,et al.  Differential αv integrin–mediated Ras-ERK signaling during two pathways of angiogenesis , 2003, The Journal of cell biology.

[29]  R. Soldi,et al.  Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor‐2 , 1999, The EMBO journal.

[30]  D. Stupack,et al.  A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. , 2006, The Journal of clinical investigation.

[31]  S. Caruthers,et al.  Minute dosages of ανβ3‐targeted fumagillin nanoparticles impair Vx‐2 tumor angiogenesis and development in rabbits , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  J. Qin,et al.  VEGF-integrin interplay controls tumor growth and vascularization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  L. Trusolino,et al.  β4 integrin activates a Shp2–Src signaling pathway that sustains HGF-induced anchorage-independent growth , 2006, The Journal of cell biology.

[34]  M. Berger,et al.  Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. , 2004, Cancer research.

[35]  G. Thomas,et al.  alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. , 2008, Cancer research.

[36]  R. Timpl,et al.  Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. , 1992, European journal of biochemistry.

[37]  I. Jurisica,et al.  Integrin α11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells , 2007, Proceedings of the National Academy of Sciences.

[38]  Fadlo R Khuri,et al.  Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. , 2006, Cancer research.

[39]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  F. Sarkar,et al.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.

[41]  Alessia Pica,et al.  Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Frisch,et al.  Anoikis mechanisms. , 2001, Current opinion in cell biology.

[43]  Zaverio M. Ruggeri,et al.  Role of 3 Integrins in Melanoma Cell Adhesion to Activated Platelets under Flow (*) , 1996, The Journal of Biological Chemistry.

[44]  J. Lindsey,et al.  HGF and ligation of αvβ5 integrin induce a novel, cancer cell-specific gene expression required for cell scattering , 2004 .

[45]  P. Houghton,et al.  Potentiation of neuroblastoma metastasis by loss of caspase-8 , 2006, Nature.

[46]  S. Hanks,et al.  Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. , 2009, Cancer research.

[47]  D. Cheresh,et al.  Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. , 1992, The Journal of clinical investigation.

[48]  M. Chellaiah,et al.  Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. , 2006, Experimental cell research.

[49]  Wenjie Bao,et al.  Integrin αv-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen , 2004, The Journal of cell biology.

[50]  R. Baron,et al.  Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases , 2007 .

[51]  M. Bouvet,et al.  Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells. , 2007, Surgery.

[52]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[53]  Yan Ning,et al.  Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. , 2005, Cancer research.

[54]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[55]  W. Oyen,et al.  αvβ3 Integrin‐targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide , 2007 .

[56]  Luzhe Sun,et al.  Control of Type II Transforming Growth Factor-β Receptor Expression by Integrin Ligation* , 1999, The Journal of Biological Chemistry.

[57]  J Engel,et al.  Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. , 1994, The Journal of biological chemistry.

[58]  M. Trikha,et al.  CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.

[59]  Andrew J. Lindsay,et al.  Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments , 2008, The Journal of cell biology.

[60]  B. Saville,et al.  Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-αv Integrin Monoclonal Antibody, Despite Widespread Tissue Binding , 2005, Clinical Cancer Research.

[61]  R. Klemke,et al.  Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. , 1997, The Journal of clinical investigation.

[62]  D. Taverna,et al.  Increased primary tumor growth in mice null for β3- or β3/β5-integrins or selectins , 2004 .

[63]  D. Jonas,et al.  CXCR4 Chemokine Receptor Mediates Prostate Tumor Cell Adhesion through α5 and β3 Integrins , 2006 .

[64]  D. Shaw,et al.  Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours , 2006, British Journal of Cancer.

[65]  Horst Kessler,et al.  N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .

[66]  Wolfhard Semmler,et al.  Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. , 2007, Cancer research.

[67]  L. Liotta,et al.  Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells , 1990, The Journal of cell biology.

[68]  S. Teitelbaum,et al.  Unoccupied αvβ3 Integrin Regulates Osteoclast Apoptosis by Transmitting a Positive Death Signal , 2005 .

[69]  Jan G. Hengstler,et al.  ERBB2-Mediated Transcriptional Up-regulation of the α5β1 Integrin Fibronectin Receptor Promotes Tumor Cell Survival Under Adverse Conditions , 2006 .

[70]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[71]  M. Wicha,et al.  Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. , 2009, Cancer research.

[72]  Michele Pagano,et al.  Role of the F-Box Protein Skp2 in Adhesion-Dependent Cell Cycle Progression , 2001, The Journal of cell biology.

[73]  Milind Rajopadhye,et al.  Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.

[74]  A. Tolcher,et al.  Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.

[75]  R. Dubridge,et al.  Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits , 2008, Investigational New Drugs.

[76]  Christopher D. Manning,et al.  αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models , 2007, Clinical Cancer Research.

[77]  A. Mercurio,et al.  The Met Receptor and α6β4 Integrin Can Function Independently to Promote Carcinoma Invasion* , 2004, Journal of Biological Chemistry.

[78]  G. Christofori,et al.  Increased tumor cell dissemination and cellular senescence in the absence of β1‐integrin function , 2007, The EMBO journal.

[79]  T. MacDonald,et al.  Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  J. Menéndez,et al.  αVβ3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer , 2005, Oncogene.

[81]  R. Assoian,et al.  Growth control by intracellular tension and extracellular stiffness. , 2008, Trends in cell biology.

[82]  W. Gerald,et al.  Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. , 2009, The Journal of clinical investigation.

[83]  B. Garmy-Susini,et al.  Integrin α4β1 Promotes Monocyte Trafficking and Angiogenesis in Tumors , 2006 .

[84]  Milan Makale,et al.  Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis , 2008, Proceedings of the National Academy of Sciences.

[85]  J. Sosman,et al.  A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, {+/-} dacarbazine (DTIC) in patients with metastatic melanoma (MM) , 2005 .

[86]  D. Ribatti.  The contribution of Harold F. Dvorak to the study of tumor angiogenesis and stroma generation mechanisms. , 2007, Endothelium : journal of endothelial cell research.

[87]  F. Giancotti,et al.  Elevated levels of the α 5 β 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells , 1990, Cell.

[88]  G. Inghirami,et al.  β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis , 2006, Cell.

[89]  S. Lim,et al.  Distinct FAK-Src activation events promote α5β1 and α4β1 integrin-stimulated neuroblastoma cell motility , 2008, Oncogene.

[90]  J. Massagué,et al.  Cell adhesion protein receptors as targets for transforming growth factor-β action , 1987, Cell.

[91]  L. Trusolino,et al.  Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. , 2005, Cancer research.

[92]  E. Danen,et al.  Emergence of α5β1 fibronectin‐ and αvβ3 vitronectin‐receptor expression in melanocytic tumour progression , 1994 .

[93]  Hiroyuki Shimada,et al.  Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.

[94]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[95]  A. Sonnenberg,et al.  Integrin αvβ3 Controls Activity and Oncogenic Potential of Primed c-Src , 2007 .

[96]  F. Ross,et al.  Superactivation of integrin alphavbeta3 by low antagonist concentrations. , 2001, Journal of cell science.

[97]  D. McDonald,et al.  Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.

[98]  D. Aebersold,et al.  Correlation between the tumoral expression of β3-integrin and outcome in cervical cancer patients who had undergone radiotherapy , 2004, British Journal of Cancer.

[99]  J W Smith,et al.  Integrin activation controls metastasis in human breast cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Massimo Cristofanilli,et al.  β4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer , 2005, Modern Pathology.

[101]  W. Cai,et al.  In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin αvβ3 , 2006 .

[102]  Z. Hua,et al.  Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature , 2008, Molecular Cancer Therapeutics.

[103]  K. Yamada,et al.  Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors , 1996, The Journal of cell biology.

[104]  K. Legate,et al.  ILK, PINCH and parvin: the tIPP of integrin signalling , 2006, Nature Reviews Molecular Cell Biology.

[105]  S. Dixon,et al.  Effects of Vitaxin®, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro , 2007, Journal of cellular biochemistry.

[106]  G. Krissansen,et al.  Antisense integrin αV and β3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas , 2007 .

[107]  Peter S. Conti,et al.  MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[108]  P. del Vecchio,et al.  Fibronectin fragments released from phorbol ester-stimulated pulmonary artery endothelial cell monolayers promote neutrophil chemotaxis. , 1991, Immunology.

[109]  R. Stupp,et al.  Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM) , 2007 .

[110]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[111]  E. Ruoslahti,et al.  Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor , 1985, Cell.

[112]  A. Oberg,et al.  Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  E. Ruoslahti,et al.  αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF , 1997 .

[114]  E. Danen,et al.  Integrin beta 3 cDNA transfection into a highly metastatic alpha v beta 3-negative human melanoma cell line inhibits invasion and experimental metastasis. , 1996, Biochemical and biophysical research communications.

[115]  David A. Cheresh,et al.  Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins , 2001, The Journal of cell biology.

[116]  M. Tomasson,et al.  Platelet and osteoclast β3 integrins are critical for bone metastasis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Ryan Park,et al.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[118]  D. Griggs,et al.  A small molecule antagonist of the αvβ3 integrin suppresses MDA-MB-435 skeletal metastasis , 2004, Clinical & Experimental Metastasis.

[119]  D. Cheresh.  Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[120]  T. Byzova,et al.  The angiogenic response is dictated by β3 integrin on bone marrow–derived cells , 2008, The Journal of cell biology.

[121]  Horst Kessler,et al.  Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.

[122]  N. Fausto,et al.  NF-κB Mediates αvβ3 Integrin-induced Endothelial Cell Survival , 1998, The Journal of cell biology.

[123]  George E. Davis,et al.  Affinity of integrins for damaged extracellular matrix: αvβ3 binds to denatured collagen type I through RGD sites , 1992 .

[124]  J. Visvader,et al.  The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. , 2008, Cancer research.

[125]  K. Friedrichs,et al.  High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. , 1995, Cancer research.

[126]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[127]  L. Trusolino,et al.  A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth , 2001, Cell.

[128]  D. Elder,et al.  Integrin Distribution in Malignant Melanoma : Association of the ß 3 Subunit with Tumor Progression 1 , 2006 .

[129]  C. Miranti,et al.  Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases , 2006, Oncogene.

[130]  J. Burger,et al.  CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells , 2005, Oncogene.

[131]  J. Iredale,et al.  The Desmoplastic Reaction Surrounding Hepatic Colorectal Adenocarcinoma Metastases Aids Tumor Growth and Survival via αv Integrin Ligation , 2008, Clinical Cancer Research.

[132]  A. Pozzi,et al.  Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. , 2009, Cancer research.

[133]  R. Dubridge,et al.  A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo , 2007, Journal of Translational Medicine.

[134]  D. Griggs,et al.  Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247 , 2004, Clinical & Experimental Metastasis.

[135]  J. Uhm,et al.  Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[136]  L. Hudson,et al.  Activated Epidermal Growth Factor Receptor Induces Integrin α2 Internalization via Caveolae/Raft-dependent Endocytic Pathway* , 2007, Journal of Biological Chemistry.

[137]  A. Skretting,et al.  Integrin scintimammography using a dedicated breast imaging, solid‐state γ‐camera and 99mTc‐labelled NC100692 , 2008, Clinical physiology and functional imaging.

[138]  B. Garmy-Susini,et al.  Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.

[139]  A. Gorter,et al.  Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival , 2007 .

[140]  Joe W Gray,et al.  Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. , 2006, Cancer research.

[141]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[142]  G. Giannelli,et al.  Targeting transforming growth factor (TGF)‐βRI inhibits activation of β1 integrin and blocks vascular invasion in hepatocellular carcinoma , 2009, Hepatology.

[143]  W. Muller,et al.  Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. , 2004, Cancer cell.

[144]  Christopher S. Chen,et al.  Rac-dependent cyclin D1 gene expression regulated by cadherin- and integrin-mediated adhesion , 2008, Journal of Cell Science.

[145]  E. Wayner,et al.  Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface , 1991, The Journal of cell biology.

[146]  D. Schlaepfer,et al.  Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.

[147]  P. Oettgen,et al.  Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. , 2005, The Journal of clinical investigation.

[148]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  Jianhua Huang,et al.  A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.

[150]  A. Sonnenberg,et al.  Integrins Uncouple Src-induced Morphological and Oncogenic Transformation* , 2008, Journal of Biological Chemistry.

[151]  F. Mitjans,et al.  Integrin αVβ3 Promotes M21 Melanoma Growth in Human Skin by Regulating Tumor Cell Survival , 1999 .

[152]  N. Kohno,et al.  Significance of Integrin α5 Gene Expression as a Prognostic Factor in Node-negative Non-Small Cell Lung Cancer , 2000 .

[153]  J. Norman,et al.  αvβ3 and α5β1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration , 2007, The Journal of cell biology.

[154]  D. Hicklin,et al.  Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice , 2004, Cancer Research.

[155]  Robin L. Anderson,et al.  Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone , 2006, Breast Cancer Research.

[156]  Jens Eickhoff,et al.  Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion , 2005, Clinical Cancer Research.

[157]  D. Tarin,et al.  Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression , 2009, Nature Medicine.

[158]  D. Cheresh,et al.  Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. , 1990, The Journal of biological chemistry.

[159]  F. Ross,et al.  Superactivation of integrin (α)v(β)3 by low antagonist concentrations , 2001 .

[160]  C. Giachelli,et al.  Src Kinase Activity Is Required for Integrin αVβ3-Mediated Activation of Nuclear Factor-κB* , 2005, Journal of Biological Chemistry.

[161]  F. McCabe,et al.  CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells , 2007, Clinical & Experimental Metastasis.

[162]  T. Byzova,et al.  Mechanisms of Integrin–Vascular Endothelial Growth Factor Receptor Cross-Activation in Angiogenesis , 2007, Circulation research.

[163]  R. Timpl,et al.  Arg‐Gly‐Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 , 1991, FEBS letters.

[164]  R. Hwang,et al.  Integrin α4β1–VCAM-1–mediated adhesion between endothelial and mural cells is required for blood vessel maturation , 2005 .

[165]  A. Shilkaitis,et al.  Molecular prognostic markers in intermediate‐thickness cutaneous malignant melanoma , 1999, Cancer.

[166]  L. Ellis,et al.  Inhibition of integrin α5β1 function with a small peptide (ATN‐161) plus continuous 5‐FU infusion reduces colorectal liver metastases and improves survival in mice , 2003, International journal of cancer.

[167]  E. Ruoslahti,et al.  Platelet-derived Growth Factor Receptor β and Vascular Endothelial Growth Factor Receptor 2 Bind to the β3Integrin through Its Extracellular Domain* , 2000, The Journal of Biological Chemistry.

[168]  M. Conaway,et al.  Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. , 2009, Cancer research.

[169]  T. Mikkelsen,et al.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  D. Taverna,et al.  A Direct Test of Potential Roles for β3 and β5 Integrins in Growth and Metastasis of Murine Mammary Carcinomas , 2005 .

[171]  W. Schiemann,et al.  Src phosphorylates Tyr284 in tgf-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion , 2007 .

[172]  S. Kuwada.  Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. , 2007, Current opinion in molecular therapeutics.

[173]  A. Gown,et al.  Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. , 2008, Cancer research.

[174]  M. Imamura,et al.  Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. , 2002, Pancreas.

[175]  E. Ruoslahti,et al.  A Signaling Pathway from the α5β1 and αvβ3 Integrins That Elevatesbcl-2 Transcription* , 2001, The Journal of Biological Chemistry.

[176]  D. Stupack,et al.  Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli , 2003, Science.

[177]  Kenneth M. Yamada,et al.  Cell–matrix adhesion , 2007, Journal of cellular physiology.

[178]  P. Black,et al.  αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .

[179]  S. Kitazawa,et al.  Integrin αvβ3 Expression by Bone‐residing Breast Cancer Metastases , 1996 .

[180]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[181]  L. Ellis,et al.  αvβ3 Integrin Antagonist S247 Decreases Colon Cancer Metastasis and Angiogenesis and Improves Survival in Mice , 2003 .

[182]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[183]  S. Barry,et al.  The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. , 2003, The Biochemical journal.

[184]  F. Aoudjit,et al.  Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells , 2001, Oncogene.

[185]  R. Juliano,et al.  Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. , 1995, Molecular biology of the cell.

[186]  Liz Y. Han,et al.  Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer , 2008 .

[187]  L. Silengo,et al.  Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion‐dependent cell survival , 1998, The EMBO journal.

[188]  R. Cardiff,et al.  Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression , 2007, Proceedings of the National Academy of Sciences.

[189]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.

[190]  N. Watanabe,et al.  Reconstructing and Deconstructing Agonist-Induced Activation of Integrin αIIbβ3 , 2006, Current Biology.

[191]  R. Klemke,et al.  Receptor Tyrosine Kinase Signaling Required for Integrin c v/35-directed Cell Motility but Not Adhesion on Vitronectin , 1994 .

[192]  P. Kiener,et al.  Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™ , 2006, Molecular Cancer Therapeutics.

[193]  D. Elder,et al.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. , 1990, Cancer research.

[194]  D. Shaw,et al.  A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo , 2006, Molecular Cancer Therapeutics.

[195]  T. Byzova,et al.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins. , 2000, Molecular cell.

[196]  D. Elder,et al.  Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. , 1998, The American journal of pathology.

[197]  K. Pienta,et al.  Expression and activation of αvβ3 integrins by SDF‐1/CXC12 increases the aggressiveness of prostate cancer cells , 2007 .

[198]  E. Raymond,et al.  Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors , 2008, Investigational New Drugs.

[199]  R. Klemke,et al.  Receptor tyrosine kinase signaling required for integrin alpha v beta 5- directed cell motility but not adhesion on vitronectin , 1994, The Journal of cell biology.